| Field | Specification |
|---|---|
| Target | |
| Alternative names | ACTN1; Alpha-actinin-1; Alpha-actinin cytoskeletal isoform; F-actin cross-linking protein; Non-muscle alpha-actinin-1; ACTN2; Alpha-actinin-2; Alpha-actinin skeletal muscle isoform 2; F-actin cross-linking protein; ACTN3; Alpha-actinin-3; A |
| Gene ID | |
| Host | |
| Clonality | |
| Isotype | |
| Reactivity | |
| Applications | |
| Immunogen | The antiserum was produced against synthesized peptide derived from human ACTN1/2/3/4. AA range:21-70 |
| Conjugate | |
| Concentration | |
| Storage | |
| Catalog no. (Mfr.) | |
| Main SKU |
Scientific Background
Alpha actinins belong to the spectrin gene superfamily which represents a diverse group of cytoskeletal proteins, including the alpha and beta spectrins and dystrophins. Alpha actinin is an actin-binding protein with multiple roles in different cell types. In nonmuscle cells, the cytoskeletal isoform is found along microfilament bundles and adherens-type junctions, where it is involved in binding actin to the membrane. In contrast, skeletal, cardiac, and smooth muscle isoforms are localized to the Z-disc and analogous dense bodies, where they help anchor the myofibrillar actin filaments. This gene encodes a nonmuscle, cytoskeletal, alpha actinin isoform and maps to the same site as the structurally similar erythroid beta spectrin gene. Three transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Jul 2008],
Product Overview
This polyclonal antibody, raised in Rabbit, recognizes Actinin-α1/2/3/4. It is validated for Western Blot, Immunohistochemistry, Immunofluorescence, ELISA.
Validated Applications
| Applications | Western Blot, Immunohistochemistry, Immunofluorescence, ELISA |
|---|---|
| Western Blot | 1/500 - 1/2000. Immunohistochemistry: 1/100 - 1/300. ELISA: 1/20000. Not yet tested in other applications. |
Optimal dilutions should be determined by the end user for each application and sample type.
Immunogen
The antiserum was produced against synthesized peptide derived from human ACTN1/2/3/4. AA range:21-70
Specifications
| Host | Rabbit |
|---|---|
| Clonality | Polyclonal |
| Isotype | IgG |
| Conjugate | Unconjugated |
| Reactivity | Human, Mouse, Rat |
| Immunogen | The antiserum was produced against synthesized peptide derived from human ACTN1/2/3/4. AA range:21-70 |
| Concentration | 1 mg/mL |
| Observed Band | 75kD |
| Subcellular Location | Cytoplasm, cytoskeleton . Cytoplasm, myofibril, sarcomere, Z line . Cell membrane . Cell junction . Cell projection, ruffle . Colocalizes with MYOZ2 and PPP3CA at the Z-line of heart and skeletal muscle. Colocalizes with PSD in membrane ruffles and central reticular structures. . |
| Swiss-Prot | P12814, P35609, Q08043, O43707 |
| Gene ID | 87, 88, 89, 81 |
| Storage | -20°C/1 year |
Reactivity Notes
Validated reactivity: Human, Mouse, Rat. For other species, epitope conservation may allow cross-reactivity; confirm with appropriate controls.
Safety & Handling
This product is for research use only (RUO) and is not intended for diagnostic or therapeutic use. The formulation contains sodium azide; handle with standard laboratory precautions.
Related Products
Explore related antibodies and reagents for Actinin-α1/2/3/4 research from ELK Biotechnology, or contact us for alternative formats.
Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.
